tetano
Editor, Senior Moderator
Clin Transl Immunology
. 2024 May 20;13(5):e1514.
doi: 10.1002/cti2.1514. eCollection 2024. From intramuscular to nasal: unleashing the potential of nasal spray vaccines against coronavirus disease 2019
Ge Jin[SUP] 1 2 [/SUP], Runze Wang[SUP] 2 [/SUP], Yi Jin[SUP] 3 [/SUP], Yingqiu Song[SUP] 2 [/SUP], Tianlu Wang[SUP] 1 2 4 [/SUP]
Affiliations
Coronavirus disease 2019, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has affected 700 million people worldwide since its outbreak in 2019. The current pandemic strains, including Omicron and its large subvariant series, exhibit strong transmission and stealth. After entering the human body, the virus first infects nasal epithelial cells and invades host cells through the angiotensin-converting enzyme 2 receptor and transmembrane serine protease 2 on the host cell surface. The nasal cavity is an important body part that protects against the virus. Immunisation of the nasal mucosa produces immunoglobulin A antibodies that effectively neutralise viruses. Saline nasal irrigation, a type of physical therapy, can reduce the viral load in the nasal cavity and prevent viral infections to some extent. As a commonly used means to fight SARS-CoV-2, the intramuscular (IM) vaccine can induce the human body to produce a systemic immune response and immunoglobulin G antibody; however, the antibody is difficult to distribute to the nasal mucosa in time and cannot achieve a good preventive effect. Intranasal (IN) vaccines compensate for the shortcomings of IM vaccines, induce mucosal immune responses, and have a better effect in preventing infection. In this review, we discuss the nasal defence barrier, the harm caused by SARS-CoV-2, the mechanism of its invasion into host cells, nasal cleaning, IM vaccines and IN vaccines, and suggest increasing the development of IN vaccines, and use of IN vaccines as a supplement to IM vaccines.
Keywords: COVID‐19; SARS‐CoV‐2; immunity; nasal cavity; vaccine.
. 2024 May 20;13(5):e1514.
doi: 10.1002/cti2.1514. eCollection 2024. From intramuscular to nasal: unleashing the potential of nasal spray vaccines against coronavirus disease 2019
Ge Jin[SUP] 1 2 [/SUP], Runze Wang[SUP] 2 [/SUP], Yi Jin[SUP] 3 [/SUP], Yingqiu Song[SUP] 2 [/SUP], Tianlu Wang[SUP] 1 2 4 [/SUP]
Affiliations
- PMID: 38770238
- PMCID: PMC11103645
- DOI: 10.1002/cti2.1514
Coronavirus disease 2019, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has affected 700 million people worldwide since its outbreak in 2019. The current pandemic strains, including Omicron and its large subvariant series, exhibit strong transmission and stealth. After entering the human body, the virus first infects nasal epithelial cells and invades host cells through the angiotensin-converting enzyme 2 receptor and transmembrane serine protease 2 on the host cell surface. The nasal cavity is an important body part that protects against the virus. Immunisation of the nasal mucosa produces immunoglobulin A antibodies that effectively neutralise viruses. Saline nasal irrigation, a type of physical therapy, can reduce the viral load in the nasal cavity and prevent viral infections to some extent. As a commonly used means to fight SARS-CoV-2, the intramuscular (IM) vaccine can induce the human body to produce a systemic immune response and immunoglobulin G antibody; however, the antibody is difficult to distribute to the nasal mucosa in time and cannot achieve a good preventive effect. Intranasal (IN) vaccines compensate for the shortcomings of IM vaccines, induce mucosal immune responses, and have a better effect in preventing infection. In this review, we discuss the nasal defence barrier, the harm caused by SARS-CoV-2, the mechanism of its invasion into host cells, nasal cleaning, IM vaccines and IN vaccines, and suggest increasing the development of IN vaccines, and use of IN vaccines as a supplement to IM vaccines.
Keywords: COVID‐19; SARS‐CoV‐2; immunity; nasal cavity; vaccine.